Some patients report lighter or irregular periods during rapid weight loss, a phenomenon that is independent of tirzepatide and related to overall caloric deficit
Instead of assigning these services to a different clinical or New Technology APC based on the very few claims available, we proposed to continue maintaining the New Technology APC assignment for each service from the prior year
Once submitted, a licensed medical provider reviews your case within just a few business hours
In summary, Ozempic is the product of decades of research into incretin hormones a culmination that has delivered a novel therapy improving the lives of many with diabetes and obesity
The FDA label advises that "the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tirzepatide and any potential adverse effects on the breastfed infant from tirzepatide or from the underlying maternal condition." This guidance places decision-making responsibility on the healthcare provider and patient, requiring individualized risk-benefit assessment
It may also impede weight loss efforts, reducing the medications benefit in managing obesity
